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As epitope mimics, mimotopes have been widely utilized in the study of epitope prediction and the development of new
diagnostics,therapeutics,andvaccines.Screeningtherandompeptidelibrariesconstructedwithphagedisplayoranyothersurface
display technologies provides an eﬃcient and convenient approach to acquire mimotopes. However, target-unrelated peptides
creep into mimotopes from time to time through binding to contaminants or other components of the screening system. In this
study, we present SAROTUP, a free web tool for scanning, reporting and excluding possible target-unrelated peptides from real
mimotopes. Preliminary tests show that SAROTUP is eﬃcient and capable of improving the accuracy of mimotope-based epitope
mapping. It is also helpful for the development of mimotope-based diagnostics, therapeutics, and vaccines.
1.Introduction
In 1985, Smith pioneered phage display technology, an in
vitro methodology and system for presenting, selecting and
evolving proteins and peptides displayed on the surface of
phage virion [1]. Since then, phage display has developed
rapidly and become an increasingly popular tool for both
basic research such as the exploration of protein-protein
interaction networks and sites [2–4], and applied research
such as the development of new diagnostics, therapeutics,
and vaccines [5–10]. Usually, the protein used to screen the
phage display library is termed as target and the genuine
partner binding to the target is called template. Peptide
mimicking the binding site on the template and binding to
the target is deﬁned as mimotope, which was ﬁrst introduced
by Geysen et al. [11]. One type of the most frequently used
targetsismonoclonalantibody.Inthissituation,thetemplate
is the corresponding antigen inducing the antibody, and
the mimotope is a mimic of the genuine epitope. In fact,
the original deﬁnition of mimotope given by Geysen et al.
goes “A mimotope is deﬁned as a molecule able to bind
to the antigen combining site of an antibody molecule, not
necessarily identical with the epitope inducing the antibody,
but an acceptable mimic of the essential features of the
epitope [11].” Mimotopes and the corresponding epitope are
considered to have similar physicochemical properties and
spatial organization. The mimicry between mimotopes and
genuine epitope makes mimotopes reasonable solutions to
epitope mapping, network inferring, and new diagnostics,
therapeutics, and vaccines developing.
Powered by phage display technology, mimotopes can
be acquired in a relatively cheap, eﬃcient and convenient
way, that is, screening phage-displayed random peptides
libraries with a given target. However, not all phages selected
out are target-speciﬁc, because the target itself is only one
component of the screening system [12]. From time to time,
phages reacting with contaminants in the target sample or
other components of the screening system such as the solid
phase (e.g., plastic plates) and the capturing molecule (e.g.,
streptavidin, secondary antibody) rather than binding to the
actual target are recovered with those target-speciﬁc binders
(displaying mimotopes) during the rounds of panning.
Peptidesdisplayedonthesephagesarecalledtarget-unrelated
peptides (TUP), a term coined recently by Menendez and
Scott in a review [12].
The results from phage display technology might be a
mixture of target-unrelated peptides and mimotopes, and it
can be diﬃcult to discriminate TUP from mimotopes since
the binding assays used to conﬁrm the aﬃnity of peptides
for the target often employ the same components as the2 Journal of Biomedicine and Biotechnology
initial panning experiment [12]. Therefore, target-unrelated
peptides might be taken into study as mimotopes if the
researchers are not careful enough. Undoubtedly, this will
make the conclusion of the study dubious. Several such
examples have been discussed in references [12, 13]. Obvi-
ously, target-unrelated peptides are not appropriate candi-
dates for the development of new diagnostics, therapeutics,
and vaccines. For mimotope-based epitope mapping, target-
unrelated peptides are main noise. If TUP is included in the
mapping, the input data is improper and the result might
be misleading [14]. There are now quite a few programs for
mimotope based epitope mapping, none of them, however,
has a procedure to scan, report and exclude target-unrelated
peptides [15–23].
In this study, we describe a web server named SAROTUP,
which is an acronym for “Scanner And Reporter Of Target-
Unrelated Peptides”. SAROTUP was coded with Perl as
a CGI program and can be freely accessed and used to
scan peptides acquired from phage display technology. It
is capable of ﬁnding, reporting, and precluding possible
target-unrelated peptides, which is very helpful for the
development of mimotope-based diagnostics, therapeutics,
and vaccines. The power and eﬃciency of SAROTUP was
also demonstrated by preliminary tests in the present study.
2.MaterialsandMethods
2.1. Compilation of TUP Motifs. Recently, Menendez and
Scott reviewed a collection of target-unrelated peptides
recovered in the screening of phage-displayed random
peptide libraries with antibodies [12]. They divided their
collectionintoseveralcategoriesaccordingtothecomponent
of the screening system to which target-unrelated peptides
bind. They also derived one or more TUP motifs for each
category. Very recently, Brammer et al. reported a completely
new type of target-unrelated peptides [13]. In the review of
Menendez and Scott, target-unrelated selection is due to the
binding to contaminants or components other than target;
however, in the report of Brammer et al., target-unrelated




of antibody, 3 motifs speciﬁc for the screening solid phase,
2 motifs speciﬁc for the contaminants in the target sample,
and 1 motif for a mutation in phage library (Table 1). All
motifs are presented in patterns according to Prosite format
[24].
2.2. Implementation of SAROTUP. The SAROTUP was
implemented as a free online service, powered by Apache
and Perl. Three pages are designed and integrated into a
tabbed web interface with cascading style sheets codes. The
core program of SAROTUP was sar.pl, a CGI script coded
with Perl. In this script, the 23 TUP motifs were converted
to regular expressions, which were then used to match each
input peptide sequence.
2.3. Construction of Test Data Sets. We constructed two-test
data sets from [12, 13, 15–23, 25, 26]. The ﬁrst data set
contains 8 cases; 6 of them are sourced from test cases used
in extant programs for mimotope-based epitope mapping
[15–23]; the left 2 are cases studies published recently [25,
26]. As shown in Table 2, the target of each case in the
ﬁrst data set is monoclonal antibody and the structure of
corresponding antigen-antibody complex has been resolved,
which is used to derive its structural epitope as the golden
standard for evaluation. For each case, there is one or more
sets of peptides recovered from phage display technology.
T h e s ep e p t i d e sh a v eb e e nu s e di nm i m o t o p e - b a s e de p i t o p e
mapping by other researchers. We scanned each set of
peptides with SAROTUP. If target-unrelated peptides were
found,anewpanelofpeptidesexcludingTUPwasproduced.
The old and the new panel of peptides were then used to
predict epitope using Mapitope or PepSurf [15, 21, 22].
Finally, the results were compared to show if SAROTUP
could improve the performance of mimotope-based epitope
mapping.
The second data set is composed of 100 peptides in
raw sequence format. It has two groups. The ﬁrst group
has 77 sequences compiled from the ﬁrst data set without
any known TUP motifs; the second group has 23 sequences
sourced from [12, 13] with various TUP motifs. The mixture
of the two groups of sequences made the second data set,
which was then used as the sample input and can be used
to evaluate the eﬃciency of SAROTUP.
3. Results and Discussion
3.1. Web Interface of SAROTUP. As a free online service,
the web interface of SAROTUP has successfully been imple-
mented as a tabbed web page. The left tab is the default page,
providing a brief introduction to this web service. The right
tab is a more detailed help page. Click the middle tab will
display a web form. The upper section of the form is for
basic input (Figure 1). The users can either paste a set of
peptide sequences in the text box or upload a sequence ﬁle
to the SAROTUP server for scanning. As shown in Figure 1,
a panel of peptides in raw sequence format taken from
the b12 test case was pasted in the text box. Besides the
raw sequences, SAROTUP also supports peptides in FASTA
format. However, only the standard IUPAC one-letter amino
acid codes are accepted at present.
The lower section of the form has a series of options
(Figure 2).Itincludesthreedroplistsforthescreeningtarget,
screened library, and screening solid phase, respectively. It
also has two groups of check boxes for the capturing reagents
and contaminants in the target sample or screening system.
By default, SAROTUP will scan each peptide against all the
known 23 TUP motifs. However, the users can customize
their scan according to their experiment at this section.
After the users submit their request, the scanning results
of SAROTUP will be displayed on the middle tabbed page.
If any target-unrelated peptides are found, they will be
reported in a table. At the same time, a new panel of peptides
excluding target-unrelated peptides is produced and can beJournal of Biomedicine and Biotechnology 3
Table 1: Known patterns of target-unrelated peptides.
TUP Category TUP Pattern Mechanism in brief
Capturing agents
H-P-[QM], G-D-[WF]-x-F, W-x-W-L, E-P- Binding to streptavidin
D-W-[FY], D-V-E-x-W-[LIV]
W-x-P-P-F-[RK] Binding to biotin
W-[TS]-[LI]-x(2)-H-[RK] Binding to Protein A
R-T-[LI]-[TS]-K-P, [LFW]-x-F-Q, W-I-S- Binding to secondary antibody
x(2)-D-W, Q-[LV]-[LV]-Q, RTYK
Constant region of antibody (the target) S-S-[IL], GELVW, G-[LI]-T-D-[WY], Binding to the Fc fragment
[RHK]-P-S-P, P-S-P-[RK]
Screening solid phase W-x(2)-W, WHWRLPS, F-H-x(2)-W Binding to plastic
Contaminants in the target sample F-H-E-x-W-P-[ST] Binding to contaminant bovine serum albumin
QSYP Binding to contaminant bovine IgG
Phage mutation HAIYPRH Growing faster than other phages
Table 2: A summary of the ﬁrst test data set for SAROTUP.
Target Template Complex Peptides Source
17b HIV gp120 envelope glycoprotein (gp120) 1GC1 11 [15]
trastuzumab human receptor tyrosine-protein kinase erbB-2 (HER2) 1N8Z 5 [20]
82D6A3 human von Willebrand factor (vWF) 2ADF 5 [19]
13b5 HIV-1 capsid protein p24 1E6J 14 [15]
BO2C11 human coagulation factor VIII 1IQD 27 [19]
cetuximab human epidermal growth factor receptor 1YY9 4 [20]
80R SARS-coronavirus spike protein S1 2GHW 42 + 18 [26]
b12 HIV gp120 envelope glycoprotein (gp120) 2NY7 2 + 32 + 19 [25]
Figure 1: Snapshot of the upper section of SAROTUP.
downloaded from the hyperlink created by the SAROTUP
server (Figure 3). The ﬁle of the new panel of peptides will
be stored on the server for a month and then automatically
deleted.
We have tested SAROTUP on the Internet Explorer
(version 6.0), Mozilla Firefox (version 3.5.2), and Google
Chrome (version 3.0). Although SAROTUP looks a little bit
Figure 2: Snapshot of the lower section of SAROTUP.
diﬀerent among diﬀerent browsers, it works normally on all
browsers tested.
3.2. Power of SAROTUP. As shown in Table 2, the ﬁrst test
data set has 11 panels of peptides acquired from phage
display libraries screened with 8 targets. In the 11 panels
of peptides SAROTUP scanned, there were target-unrelated4 Journal of Biomedicine and Biotechnology
Figure 3: Snapshot of SAROTUP result page. Target-unrelated
peptides in the b12 test case are reported in the table. The new
panel of peptides excluding the target-unrelated peptides can be
downloaded from the hyperlink.
peptides in 3 panels from cetuximab, 80R, and b12 test
case, respectively (Table 3). This result suggested it was not
rare that target-unrelated peptides sneaked into biopanning
results and then were taken as mimotopes in study. In all, 7
target-unrelated peptides were found; 4 of them were due to
binding to plastic; the left 3 were due to binding to the Fc
fragment (Table 3).
For the above 3 cases, the genuine epitopes recognized
by cetuximab, 80R, and b12 monoclonal antibodies are
compiled according to the CED records [27] and PDBsum
entries[28]. Mapitope or PepSurf [15, 21, 22] were used
to perform mimotope-based epitope prediction with or
without SAROTUP procedure. For Mapitope and PepSurf
algorithm, the library type was set to “random”; the stop
codon modiﬁcation was set to “none”; and all other options
were in default. The cluster with best score was taken as the
predicted epitope. In the cetuximab case, PepSurf was used
because there are only four or three peptides in the panel,
statistically too few for Mapitope. In the case of 80R and b12,
Mapitope was used because many peptides in the two cases
exceeding the length limit of PepSurf, that is, 14 amino acids.
If a predicted residue is identical with a residue in the true
epitope, it is underlined (Table 4).
As shown in Table 4, the number of true positives
improved from zero to four in the cetuximab case with
SAROTUP procedure. When it came to the b12 case, the
number of true positives increased from one to eight.
SAROTUP did not improve the number of true positives in
the 80R case when the parameters are same to the cetuximab
and b12 cases. However, when the distance parameter was
adjusted from default (i.e., 9 ˚ A) to 10 ˚ A, SAROTUP did
increase the number of true positive residues from eight to
eleven. These results indicate: (1) epitope prediction based
on mimotope will be interfered if target-unrelated peptides
are taken as mimotopes; (2) SAROTUP can improve the
performance of mimotope based epitope mapping through
cleaning the input data.
We also scanned the second data set to evaluate the
eﬃciencyofSAROTUP.Theseconddatasethas100peptides,
varying from 6 to 22 residues long. Suppose that matching
each pattern to each peptide manually costs 10 seconds,
then it would take a researcher more than 6 hours (23,000
seconds) to look through the second data set for target-
unrelated peptides, even if he is as prompt during the whole
period. However, it took only one second for SAROTUP
to complete this work. Besides, a table of target-unrelated
peptides and a new panel of peptides excluding TUP was
produced at the same time by SAROTUP. It is true that
some target-unrelated peptides can be identiﬁed through
control and binding competition experiments. However,
usingSAROTUPﬁrstwillcertainlysavealotoflabor,money,
and time for researchers in this area.
3.3. Extending of SAROTUP. Although the target of all
tests described previously were monoclonal antibodies,
SAROTUP can be customized and used in scanning the
results from phage display technology using other targets
such as enzymes and receptors. This is because their
screening systems are similar. For the same reason, we can
alsoexpectthatSAROTUPwillextenditsusetoothersimilar
in vitro evolution techniques, such as ribosome display [29–
31], yeast display [32], and bacterial display [33–35].
Furthermore, SAROTUP will not only beneﬁt the
mimotope-basedepitopemapping,butalsothedevelopment
of new diagnostics, therapeutics, and vaccines. Target-
unrelated peptides are not appropriate candidates for mimo-
tope based diagnostics, therapeutics, and vaccines, since they
are mimics to components or contaminants of the screening
system rather than target. Therefore, it is reasonable to
ﬁnd and exclude possible target-unrelated peptides from
the candidate list of new diagnostics, therapeutics, and
vaccines. Take the cetuximab as an example. Riemer et al.
screened a phage-displayed random peptides library with the
cetuximab and got four diﬀerent peptides, that is, QFDL-
STRRLK, QYNLSSRALK, VWQRWQKSYV, and MWDRFS-
RWYK [36]. As described previously, we scanned the four
“mimotopes” with SAROTUP and the result suggested that
the peptide VWQRWQKSYV might be a TUP. Indeed, the
dot blot analysis of Riemer et al. showed that QYNLSSRALK
boundthecetuximabwithhighaﬃnitybutVWQRWQKSYV
w a sl e s sr e a c t i v ew i t ht h ec e t u x i m a b[ 36]. Trying to develop
a mimotope vaccine, Riemer et al. synthesized two-vaccine
constructs with the peptide QYNLSSRALK and VWQR-
WQKSYV, respectively. After immunization mice with these
constructs, they found that either the cetuximab or the
antibodies induced by the QYNLSSRALK vaccine construct
inhibited the growth of A431 cancer cells signiﬁcantly. The
inhibition of the antibodies induced by the VWQRWQKSYV
vaccine construct however, was not statistically signiﬁcant
when compared with the inhibition caused by the isotype
control antibody [36].Journal of Biomedicine and Biotechnology 5
Table 3: Target-unrelated peptides in the ﬁrst test data set.
Target Target-unrelated peptides Mechanism
cetuximab VWQRWQKSYV Binding to plastic
80R CESSLCLMYSLGPPA, Binding to the Fc fragment
YSTPSSILDTHPLYK Binding to the Fc fragment
b12
NLRSTSFFELWAKWP Binding to plastic
NWPRWWEEFVDKHSS Binding to plastic
NWPRWEEFVDKHSS Binding to plastic
ICFPFNTRYCIFAMMVSSLVF Binding to the Fc fragment
Table 4: Mimotope-based epitope prediction with or without SAROTUP procedure.
Target Prediction without
SAROTUP procedure Genuine epitope Prediction with SAROTUP
procedure
cetuximab
N134, E136, S137, I138,
Q139, W140, R141, Q164,
K185, L186, T187, K188
P349, R353, L382, Q384,
Q408, H409, Q411, F412,
V417, S418, I438, S440,
G441, K443, K465, I467,
S468, N469, G471, N473
K375, I401, R403, R405,
T406, K407, Q408, H409,
G410, Q411, F412, D436
80R
H445, V458, P459, F460,
S461, P462, D463, G464,
K465, P466, C467, T468,
P469, P470, A471, L472,
N473, C474, Y475
R426, S432, Y436, K439,
Y440, Y442, P469, P470,
A471, L472, C474, Y475,
W476, L478, N479, D480,
G482, Y484, T485, T486,
T487, G488,Y491, Q492
L443, R444, H445, I455,
S456, N457, V458, P459,
F460, S461, P462, D463,
G464, K465, P466, C467,
T468, P469, P470, A471,
L472, N473, C474, Y475
b12
I108, C109, S110, L111,
D113, Q114, S115, L116,
K117, P118, C119, V120,
P206, K207, V208, S209,
F210, E211, P212, I213,
P214, I251, R252, P253,
I424, N425, M426, W427,
C428, K429, V430
N280, A281, S365, G366,
G367, D368, P369, I371,
V372, T373, Y384, N386,
P417, R419, V430, G431,
K432, T455, R456, G472,
G473, D474, M475
W95, T232, F233, N234,
T236, S257, L260, N262,
G263, S264, L265, A266,
E267, E268, E269, V270,
V271, T290, S291, S364,
S365, G366, G367, D368,
P369, E370, I371, V372,
T373, T450, S481
3.4. Cautions in Using SAROTUP. SAROTUP must be used
with caution since it is a tool only based on pattern matching
at present. There are a lot of target-unrelated peptides
bearing no known motifs [12]. As these TUPs are not
embedded in SAROTUP at present, it is possible that a true
TUP cannot be detected by SAROTUP. To reduce this kind
of false negatives, we are constructing a database for target-
unrelated peptides and mimotopes. Besides the motif-based
search, the database-based search can ﬁnd out the known
TUP without known motifs.
It is also possible that a SAROTUP predicted target
unrelated peptide is actually target-speciﬁc. To decrease this
kind of false positives, the users should customize the scan
according to their experiment at the section of advance
options. For example, the user should select “antibody
without Fc fragment” as the target if Fab was used in
biopanning; this will prevent SAROTUP from reporting
peptides bearing the Fc-binding motifs as TUP. As described
above, SAROTUP in future will also provide an exact match
tool based on database search. In this way, a match might
mean that diﬀerent research groups have isolated the same
peptidewithavarietyoftargets.Itisobviousthatthispeptide
canhardlybeatruetargetbinder.Thus,thefalsepositiverate
of SAROTUP can be decreased further when its new feature
become available.
At last, we must point out that the controlled experiment
isstillthegoldstandardtodistinguishTUPsfromthespeciﬁc
mimotopes. The report of SAROTUP should be veriﬁed with
experiment.
4. Conclusions
SAROTUP, a web application for scanning, reporting and
excluding target-unrelated peptides has been coded with
Perl. It helps researchers to predict epitope more accurately
based on mimotopes. It is also useful in the development
of diagnostics, therapeutics, and vaccines. To our knowl-
edge, SAROTUP is the ﬁrst web tool for TUP detecting
and data cleaning. It is very convenient for the com-
munity to access SAROTUP through http://immunet.cn/
sarotup/.6 Journal of Biomedicine and Biotechnology
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